APOE and Alzheimer disease: Likewise, brain imaging studies that conduct comparisons between APOE ε4 carriers and non-carriers, denoted as ε4(+) and ε4(−), respectively, in this paper, may depict premature structural and/or functional brain changes that could be taken later as early biomarkers for AD.